MedTrace Logo

Autologous Blood for Full-thickness Macular Hole

NCT05494229 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-03-27

No results posted yet for this study

Summary

Autologous blood for primary and recurrent holes

Conditions

  • Ophthalmopathy

Interventions

OTHER

Pars-plana vitrectomy

Pars-plana vitrectomy

Sponsors & Collaborators

  • Omer Othman Abdullah

    lead OTHER

Principal Investigators

  • Omer Abdullah, M.Sc. · Ibinsina Modern Eye and Retina Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-03-01
Completion
2023-03-01

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494229 on ClinicalTrials.gov